Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -26.41% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -23.34%. Over the past 30 days, the price of KRON has fallen by 3.59%. And in the last five days, it has fallen by -3.17%.
Kronos Bio Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $1.60 on 07/16/24 and the lowest value was $0.69 on 05/24/24.
52-week price history of KRON Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Kronos Bio Inc’s current trading price is -42.51% away from its 52-week high, while its distance from the 52-week low is 33.32%. The stock’s price range during this period has varied between$0.69 and $1.60. The Kronos Bio Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.26 million for the day, a figure considerably higher than their average daily volume of 0.2 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Kronos Bio Inc (KRON) has experienced a quarterly decline of -3.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 55.51M and boasts a workforce of 63 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9635, with a change in price of -0.2570. Similarly, Kronos Bio Inc recorded 173,848 in trading volume during the last 100 days, posting a change of -22.16%.
KRON’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for KRON stands at 0.23. Similarly, the long-term debt-to-equity ratio is also 0.20.
KRON Stock Stochastic Average
As of today, Kronos Bio Inc’s raw stochastic average for the last 50 days stands at 35.52%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 5.32%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 30.78% and 39.63%, respectively.
